What You Should Know:
– Ketryx, the AI-powered compliance platform helping life sciences companies ship safer products faster, today announced a $39 million Series B led by Transformation Capital, with participation from existing investors including Lightspeed Venture Partners, MIT’s E14 Fund, Ubiquity Ventures, and 53 Stations.
– This latest round brings the company’s total funding to over $55 million, and Vinay Shah, Partner and Founding Team Member at Transformation Capital, will join Ketryx’s board. Ketryx is solving one of the most urgent challenges in the life sciences: the need to release products faster and incorporate AI, without compromising safety or compliance.
Automating Compliance to Accelerate Safer, Faster Product Development in Life Sciences
Ketryx is redefining the product lifecycle for life science and medtech teams with its AI-powered compliance platform, designed to deliver safer products at speed. Already trusted by three of the world’s top five medical device manufacturers, as well as Fortune 500 companies and AI-driven enterprises including DeepHealth, Heartflow, and Aignostics, Ketryx integrates seamlessly into existing workflows to automate documentation, create traceability, and accelerate release cycles—cutting manual work by 90% while closing compliance gaps.
Purpose-built for highly regulated environments, Ketryx enables validation, traceability, and regulatory workflows in real time across the entire development lifecycle. Customers report up to a 90% reduction in documentation time and more than 10x faster product releases. By eliminating the traditional tradeoff between innovation and safety, the platform positions itself as a critical AI infrastructure layer for regulated industries worldwide.
“I’ve spent the last decade at the intersection of AI and life sciences, watching it evolve from an emerging tool to a critical application for patients,” said Erez Kaminski, CEO and Founder of Ketryx. “It’s now time to accelerate adoption and ensure AI is safe, reliable, and ready for the most regulated environments. This round is about scaling Ketryx to meet that challenge. Having Transformation Capital—one of the leading digital health growth equity firms—as our lead partner provides not only capital but also deep expertise and industry connections. With their support, we are expanding globally, accelerating our product roadmap, and growing our teams in Boston and Austria.”
Ketryx empowers organizations to implement zero-lag compliance, where validation, traceability, and documentation happen in real time, enabling faster, safer product releases. As compliance demands increase and AI reshapes development across industries, Ketryx ensures regulated teams can innovate at full speed without compromising quality or patient safety.
